Targets › NONE
4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 3; Oncology, Infectious disease, Immunology; next expected readout Mar 2027.
Open in Phaseline: the race on NONE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| New York Medical College | Metronidazole Vaginal Nitroimidazole antimicrobial that generates reactive intermediates to disrupt bacterial an | NONE | Phase 4 | Post-Op Infection | – |
| Fudan University | Carboplatin DNA-damaging alkylating agent; platinum-based chemotherapy | NONE | Phase 3 | Triple-negative Breast Cancer | Mar 2027 |
| Peter Black | ST-02 mucoadhesive gemcitabine suspension for pyelocaliceal instillation; nucleoside analog inhi | NONE | Phase 2 | Urothelial Carcinoma of the Renal Pelvis and Ureter | Apr 2028 |
| Citryll | [89Zr]Zr-CIT Radiolabeled monoclonal antibody imaging agent targeting neutrophil extracellular traps (N | NONE | Phase 2 | RA | – |
Post-Op Infection (1) Urothelial Carcinoma of the Renal Pelvis and Ureter (1) Triple-negative Breast Cancer (1) RA (1)
small molecule (4)
New York Medical College (1) Peter Black (1) Fudan University (1) Citryll (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.